This is a past event. Its details are archived for historical purposes.
The contact information may no longer be valid.
Please visit our current events listings to look for similar events by title, location, or venue.
Saturday, November 11, 2017
Physical Sciences Building, 120
245 East Avenue
Group Leader, Technologies, Targets, & Leads
Department of Chemical Biology & Therapeutics
Novartis Institutes of Biomedical Research
Host: Michelle Wang
CRISPR-based Phenotypic Screening in Drug Discovery
The Technology, Targets, & Leads group at the Novartis Institutes for Biomedical Research focuses on developing novel genomics based screening platforms. We apply these screening platforms to define cellular signaling networks in complex models of human disease to identify novel therapeutic targets. We also leverage state of the art chemical biology tools identify tool compounds. A major focus of our work is on applying CRISPR based genome editing methods for forward genetic screens in mammalian cells. I will describe my career path from structural biologist to professional drug hunter, highliting scientific work from the group to delineating novel synthetic lethal interactions in cancer, CRISPR technology development, and autophagy signaling.